Methods for the treatment of synucleinopathies

• US 20050272722A1
• Filed: 03/18/2005
• Published: 12/08/2005
• Est. Priority Date: 03/18/2004
• Status: Abandoned Application

• Current Assignee: Brigham and Women's Hospital Incorporated
• Original Assignee: Brigham and Women's Hospital Incorporated
• Inventors: Liu, Zhihua, Lansbury, Peter T.
• Application Number:
  US11/084,739
• Publication Number:
  US 20050272722A1
• Time in Patent Office: Days
• US Class Current: 514/221
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine

Abstract

Methods are provided of treating synucleinopathies, such as Parkinson'"'"'s Disease, Diffuse Lewy Body Disease and Multiple System Atrophy, comprising administering to a synucleinopathic subject a farnesyl transferase inhibitor compound.

Claims

1-11. -11. (canceled)

12. A method of treating a synucleinopathic subject, the method comprising, administering to a synucleinopathic subject a farnesyl transferase inhibitor compound of the formula:

13. The method according to claim 12, wherein

R₁ is Br, or CN;

R₂ is optionally substituted benzyl;

R₃ is optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted 2-thienyl, or optionally substituted 1-piperidinyl;

R₄ is hydrogen, or methyl;

Z₁ is CO, SO₂, or SO₂ N(R₅)—

;

R₅ is optionally substituted lower alkyl or optionally substituted phenyl;

and n is 1.

14. The method according to claim 12 wherein

R₁ is CN;

R₂ is optionally substituted benzyl;

R₃ is optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted 2-thienyl, or optionally substituted 1-piperidinyl;

R₄ is hydrogen, or methyl;

Z is CO, or SO₂; and

n is 1.

15. The method according to claim 12, wherein

R₁ is CN;

R₂ is benzyl;

R₃ is n-propyl, n-butyl, 3-methoxypropyl, 2-thienyl, 5-bromo-2-thienyl, phenyl, 4-methoxyphenyl, or 1-piperidinyl;

R₄ is hydrogen;

Z is SO₂; and

n is 1.

16. The method according to claim 12 wherein the compound is selected from the group consisting of:

(R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile;

(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-4-(1-oxobutyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine;

(R)-4-[(5-bromo-2-thienyl)sulfonyl]-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-yl methyl)-3-(phenyl methyl)-1H-1,4-benzodiazepine;

(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-yl methyl)-4-[(4-methoxyphenyl)sulfonyl]-3-(phenylmethyl)-1H-1,4-benzodiazepine;

(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenyl methyl)-4-(phenylsulfonyl)-1H-1,4-benzodiazepine;

(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(propylsulfonyl)-1H-1,4-benzodiazepine;

(R)-4-(butylsulfonyl)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine;

(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(1-piperidinylsulfonyl)-1H-1,4-benzodiazepine;

(R)-4-(3-methoxypropylsulfonyl)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine; and

pharmaceutically acceptable salts thereof.

17. The method according to claim 12 wherein the pharmaceutically acceptable salt is selected from the group consisting of the hydrochloride salt, the methanesulfonic acid salt and the trifluoroacetic acid salt.

18. The method according to claim 12 wherein the compound is (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile.

34. The method of claim 12 or 33, wherein the synucleinopathic subject has a synucleinopathy selected from the group consisting of:

Parkinson'"'"'s disease, diffuse Lewy body disease, and multiple system atrophy disorder.

35. The method of claim 34 wherein the subject is a human.

36. The method of claim 35, wherein the effective amount comprises about 10 ng/kg of body weight to about 1000 mg/kg of body weight at a frequency of administration from once a day to once a month.

37. The method of claim 36, further comprising administering to the subject an amount of one or more non-farnesyl transferase inhibitor compounds effective to treat a neurological disorder.

38. The method of claim 37, wherein each non-farnesyl transferase inhibitor compound is selected from the group consisting of:

dopamine agonist, DOPA decarboxylase inhibitor, dopamine precursor, monoamine oxidase blocker, cathechol O-methyl transferase inhibitor, anticholinergic, and NMDA antagonist.

39. The method of claim 37, wherein each non-farnesyl trasferase inhibitor compound is selected from the group consisting of Memantine, Aricept, and other acetylcholinesterase inhibitors.

44. The method of claim 34, wherein the synucleinopathy is diffuse Lewy body disease.

45. The method of claim 34, wherein the synucleinopathy is Parkinson'"'"'s disease.

19-32. -32. (canceled)

33. A method of treating a synucleinopathic subject, the method comprising, administering to a synucleinopathic subject a farnesyl transferase inhibitor compound of the formula:

40-43. -43. (canceled)